Eurofins Scientific has patented a method to detect certain cancers in individuals by analyzing cell-free DNA for specific methylated CpGs. The method can determine the presence of cancer, particularly ovarian cancer in women, and guide treatment with specific chemotherapeutic agents or surgery. GlobalData’s report on Eurofins Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Eurofins Scientific, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Eurofins Scientific's grant share as of February 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Method to detect cancer in human individual using cell-free dna
A recently granted patent (Publication Number: US11920200B2) outlines a method for detecting the presence of cancer in human individuals by analyzing cell-free DNA samples for methylation status at specific CpG sites. The patent describes a process where the presence of cancer is determined when at least one molecule of cell-free DNA is methylated at 16 CpGs. The method further includes treating the identified cancer by administering chemotherapeutic agents or performing tumor de-bulking surgery. The type of cancer and treatment options vary based on the gender of the individual, with specific cancers like breast, lung, colon, pancreatic, uterine, ovarian, and prostate cancers being targeted.
Additionally, the patent details the use of bisulfite as an agent to modify cell-free DNA based on CpG methylation status, amplification of specific nucleic acid sequences, and estimation of the fraction or ratio of methylated CpGs in the sample. The method also extends to individuals previously treated with carboplatin, where a reduced response to carboplatin therapy is determined based on methylation status at the 16 CpGs. In such cases, alternative chemotherapeutic agents are recommended for treatment. The patent emphasizes the importance of gender-specific cancer types and treatment strategies, highlighting the significance of personalized medicine in cancer care.
To know more about GlobalData’s detailed insights on Eurofins Scientific, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
